Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

After almost 50 years at Oxford, Professor Dame Kay Davies is soon to retire – well…. mostly… Kay talks to Sarah Whitebloom about her early years at Somerville fresh out of state school, how she balanced motherhood with the demands of her burgeoning career, and her long held passion to find a cure for Duchenne muscular dystrophy. Thank you Kay for your long years of service and dedication. You are truly an inspiration to many!

Professor Dame Kay Davies

In spite of everything, many people still underestimate women, in general, and older women, in particular. They have clearly never encountered Kay Davies, the dynamic 70-year-old Oxford geneticist, who is ‘retiring’ after a lifetime’s research (but not really).  Just a few minutes immersed in the company of the self-effacing-but-determined Professor Dame, is enough to make anyone exhausted and put paid to stereotypes about women.

Forget about older women being invisible, you could not miss Professor Davies, who arrives promptly for her interview, lovely in a hallmark brightly coloured jacket (more of which later).

But the professor’s story is even more arresting than her striking appearance. Having arrived in Oxford more than 50 years’ ago, Professor Davies has worked with some of the leading medical scientists of the last half century.

She has been tirelessly at the cutting-edge of genetic science; is close to a cure for a devastating genetic condition – and has found time to be a member of the Council of the Medical Research Council, Deputy Chair of the Wellcome Trust and hold a variety of other posts. Professor Davies has been honoured in the UK (a CBE, followed by a DBE in 2008) and in the US (by the American Society of Human Genetics) – oh...and she has a family.

Read the full interview with Professor Dame Kay Davies

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.